Compare Abeona Therapeutics Inc (ABEO) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Microsoft — how do they compare? Abeona Therapeutics Inc trades at $6.66 (market cap $373.32M), while Microsoft trades at $382.77 (market cap $2.89T). The key difference: Microsoft is far larger — about 7741.3× Abeona Therapeutics Inc's market cap, and Microsoft pays a 0.94% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MSFT | |
|---|---|---|
Market Cap | $373.32M | $2.89T |
Sector | Health | Technology |
52-Week High | $7.23 | $542.07 |
52-Week Low | $4.17 | $352.83 |
Enterprise Value | $228.22M | $2.87T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Microsoft (MSFT) trades at $382.19, down 1.18% over 24 hours, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with revenue growth to $281.72B in 2025 and net income of $101.83B, supported by consistent earnings beats. Analyst consensus remains overwhelmingly positive with an 80.49% buy rating and a $550.43 price target. Recent news highlights AI leadership and Azure momentum as key growth drivers.
Outlook is positive given robust financials and AI positioning, but risks include elevated capital expenditure concerns and competitive pressures. The stock offers long-term growth potential, though near-term volatility may persist amid market scrutiny of spending and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
